The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

P. vivax

Low risk of recurrence following artesunate–Sulphadoxine–pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan

March 19, 2018 - 15:48 -- Open Access
Tags: 
Author(s): 
Muzamil Mahdi Abdel Hamid, Kamala Thriemer, Benedikt Ley, et al.
Reference: 
Malaria Journal 2018 17:117, 16 March 2018

AS/SP remains effective for the treatment of P. falciparum and P. vivax.

Medical Condition: 

Correlates of HIV and malaria co-infection in Southern India

September 5, 2012 - 06:58 -- Kabogo Ndegwa
Author(s): 
Bharti AR, Saravanan S, Madhavan V, Smith DM, Sharma J, Balakrishnan P, Letendre SL, Kumarasamy N
Reference: 
Malaria Journal 2012, 11:306 (3 September 2012)

MalariaWorldRetrospective testing of stored plasma samples for malaria antibodies can facilitate identification of populations with high rates of co-infection, and in this southern India HIVinfected cohort there was a considerable burden of malaria co-infection, predominantly due to P. vivax.

Country: 
Medical Condition: 

Not Open Access | Thrombocytopenia in childhood malaria with special reference to P. vivax monoinfection: A study from Bikaner (Northwestern India)

June 21, 2012 - 09:15 -- Patrick Sampao
Author(s): 
Gajanand Singh Tanwar, Punam Chand Khatri, Dhanpat Kumar Kochar, et al.
Reference: 
Platelets, 2012, Vol. 23, No. 3 , Pages 211-216

MalariaWorldThis prospective study included 676 admitted children of malaria [Plasmodium falciparum (Pf) monoinfection 262, Plasmodium vivax (Pv) monoinfection 380, and mixed (Pf + Pv) infection 34], in which thrombocytopenia (platelet count <150 × 103/mm3 on admission) was found in 442 (65.38%) children [Pf monoinfection 55.3% (145/262), Pv monoinfection 73.16% (278/380), and mixed infection 55.88% (19/34)].

Person: 
Medical Condition: 

Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates

June 20, 2012 - 12:54 -- Kabogo Ndegwa
Author(s): 
Kang J, Ju H, Kang Y, Lee D, Moon S, Sohn W, Park J, Kim T, Na B
Reference: 
Malaria Journal 2012, 11:206 (18 June 2012)

MalariaWorldPvMSP-142 of Korean P. vivax isolates displayed allelic polymorphisms caused by mutation, recombination and balancing selection.

Country: 
Medical Condition: 

Evaluation of the rapid diagnostic test CareStart pLDH Malaria (Pf-pLDH/pan-pLDH) for the diagnosis of malaria in a reference setting

June 20, 2012 - 12:51 -- Kabogo Ndegwa
Author(s): 
Heutmekers M, Gillet P, Maltha J, Scheirlinck A, Cnops L, Bottieau E, Van Esbroeck M, Jacobs J
Reference: 
Malaria Journal 2012, 11:204 (18 June 2012)

MalariaWorldCareStart pLDH performed excellent for the detection of P. falciparum, well for P. vivax, but poor for P. ovale and P. malariae.

Medical Condition: 

Suppression of erythroid development in vitro by Plasmodium vivax

May 29, 2012 - 11:54 -- Kabogo Ndegwa
Author(s): 
Panichakul T, Payuhakrit W, Panburana P, Wongborisuth C, Hongeng S, Udomsangpetch R
Reference: 
Malaria Journal 2012, 11:173 (24 May 2012)

MalariaWorldThis study shows for the first time that P. vivax parasites inhibit erythroid development leading to ineffective erythropoiesis and highlights the potential of P. vivax to cause severe anaemia.

Medical Condition: 

Open Access | Survey for asymptomatic malaria cases in low transmission settings of Iran under elimination programme

May 2, 2012 - 08:23 -- Kabogo Ndegwa
Author(s): 
Zoghi S, Mehrizi AA, Raeisi A, Haghdoost AA, Turki H, Safari R, Ahmadi Kahanali A, Zakeri S
Reference: 
Malaria Journal 2012, 11:126 (25 April 2012)

MalariaWorldTaken together, the lack of asymptomatic carrier with the evidence of extremely low seropositive to both P. vivax and P. falciparum among examined individuals supported the limited recent transmission in the studied areas and, therefore, these parts of Iran have potential to eliminate the disease in the next few years.

Medical Condition: 

Open Access | Characterization and gene expression analysis of the cir multi-gene family of Plasmodium chabaudi chabaudi (AS)

April 2, 2012 - 14:20 -- Patrick Sampao
Author(s): 
Lawton J, Brugat T, Yam X, Reid AJ, Boehme U, Otto TD, Pain A, Jackson A, Berriman M, Cunningham D, Preiser P, Langhorne J
Reference: 
BMC Genomics 2012, 13:125 (29 March 2012)

MalariaWorldIn this model, pir genes are called cirs and may be involved in this mechanism, allowing evasion of host immune responses. In order to fully understand the role(s) of CIR proteins during P. chabaudi infection, a detailed characterization of the cir gene family was required.

Open Access | Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial

March 30, 2012 - 12:34 -- Patrick Sampao
Author(s): 
Nicolas Senn, Patricia Rarau, Ivo Mueller, et al.
Reference: 
PLoS Med 9(3): e1001195.

MalariaWorldIn this study, 1,121 Papua New Guinean infants were enrolled into a three-arm placebo-controlled randomized trial and assigned to sulfadoxine-pyrimethamine (SP) (25 mg/kg and 1.25 mg/kg) plus amodiaquine (AQ) (10 mg/kg, 3 d, n = 374), SP plus artesunate (AS) (4 mg/kg, 3 d, n = 374), or placebo (n = 373), given at 3, 6, 9 and 12 mo. Both participants and study teams were blinded to treatment allocation.

Person: 
Medical Condition: 

Pages

Subscribe to RSS - P. vivax